Let the Biologics Begin


The FDA's Jan. 31 approval of Amevive (alefacept) for chronic plaque psoriasis represents the first step down an exciting new road, said Alan Menter, M.D, medical director of the Psoriasis Research Center at Baylor University Medical Center.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.